2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5523 Two thousand patients with polycythemia vera: The Mayo Clinic and florence-crimm experiences

Giuseppe Gaetano Loscocco, MD, PhD, Naseema Gangat, MBBS2, Paola Guglielmelli, MD, PhD3, Rong He, MD4, Valentina Boldrini5, Cinthya J Zepeda Mendoza6, Giulio Capecchi7, Animesh Pardanani, PhD, MBBS8, Fernanda Di Vaio9, Francesca Gesullo10, Elena Nacca, BSc, MsC11, Alessandro Vannucchi, MD12, Ayalew Tefferi, MD13
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
3 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
4 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
7 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
8 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
9 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
10 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
11 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
12 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
13 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States

Background: Polycythemia vera (PV) carries lifelong risks of thrombosis, fibrotic progression, acute myeloid leukemia (AML), and premature death, yet large, well-annotated studies of its long-term course remain limited. We report two independent 1,000-patient Mayo Clinic and Florence-CRIMM experiences describing presentation, vascular burden, transformation, survival, and associated clinical, cytogenetic, and molecular variables.

Methods: Consecutive patients with PV were retrospectively evaluated at each institution; diagnoses were reviewed according to 2022 International Consensus Classification criteria. Baseline clinical/laboratory data, cytogenetics obtained ≤1 yr, and NGS performed ≤3 yr from diagnosis were included. Cohorts were analyzed separately. Cumulative incidences of arterial thrombosis (AT), venous thrombosis (VT), myelofibrotic transformation (MF), and AML were estimated with death as a competing event. Multivariable logistic regression evaluated vascular events at/prior to diagnosis; Cox models evaluated post-diagnosis events, transformation, and overall survival (OS).

Results: The Mayo cohort included 1,000 patients (median age 62 yr; 51% male; JAK2V617F 955, exon-12 45); 261 (26%) had major thrombosis at/prior to diagnosis. Cytogenetics/NGS were available in 438/208 patients; baseline aspirin/cytoreduction/anticoagulation use was 74/53/15% among evaluable patients. Over a median 9-yr follow-up, 95 AT and 65 VT occurred; 204 patients developed MF, 44 AML, and 370 died. Cumulative incidences of MF at 10/20/30/40 yr were 12/31/39/45%; corresponding estimates were 3/7/9/12% for AML, 8/13/16/16% for AT, and 6/9/10/12% for VT. On multivariable analysis, cardiovascular (CV) risk factors were associated with AT at/prior to diagnosis (OR 4.8; p<0.01), while age ≥60 yr predicted post-diagnosis AT (HR 2.6, 1.5-4.6; p<0.01). WBC >11×109/L was associated with MF (HR 1.4, 1.1-1.9; p=0.01) and inferior OS (HR 1.6, 1.3-1.9; p=0.04). Among NGS-annotated patients, SRSF2 was associated with MF (HR 15.1, 4.5-50.7), AML (HR 46, 4.9-436), and death (HR 12.6, 4.5-35.2; all p<0.01); ASXL1 with AML (HR 5.5, 1.2-25.6; p=0.03); and IDH2 (HR 4.9, 1.4-17.2; p=0.01) and TET2 (HR 1.8, 1.1-3.1; p=0.02) with inferior OS. Abnormal karyotype was associated with MF (HR 3.5, 1.6-7.6) and death (HR 2.1, 1.3-3.5; both p<0.01).

The Florence cohort included 1,000 patients (median age 61 yr; 57% male; JAK2V617F 986, exon-12 14); 228 (23%) had major thrombosis at/prior to diagnosis. JAK2V617F variant allele frequency (VAF)/cytogenetics/NGS were available in 900/599/570 patients; baseline aspirin/cytoreduction/anticoagulation use was 92/55/6%. Over a median 8-yr follow-up, 86 AT and 80 VT occurred; 163 patients developed MF, 28 AML, and 249 died. Cumulative incidences of MF at 10/20/30 yr were 11/32/54%; corresponding estimates were 1/4/12% for AML, 9/15/18% for AT, and 8/14/17% for VT. On multivariable analysis, age ≥60 yr and CV risk factors were associated with AT at/prior to diagnosis (OR 1.7; p=0.02 and OR 2.2; p<0.01) and during follow-up (HR 1.7, 1.1-2.9; p=0.04 and HR 2.0, 1.2-3.3; p=0.01). JAK2V617F VAF ≥50% was associated with VT (HR 2.3, 1.3-4.3; p<0.01) and MF (HR 2.6, 1.2-6.4; p=0.02), and NFE2 with MF (HR 5.1, 1.3-19; p=0.02). WBC >15×109/L (HR 3.7, 1.4-9.9; p=0.01) and SRSF2 (HR 8.8, 1.1-72; p=0.04) were associated with AML, while age ≥60 yr (HR 4.8, 2.6-9; p<0.01), WBC >11×109/L (HR 2.3, 1.3-3.9; p<0.01), and TET2 (HR 2.7, 1.6-4.6; p<0.01) were associated with inferior OS.

Conclusions: Across 2,000 patients, 489 (24%) had major thrombosis at/prior to diagnosis, 367 (18.3%) developed MF, 72 (3.6%) developed AML, and 619 (31%) died. MF incidence reached 31% and 32% at 20 yr, establishing a robust benchmark for the late burden of PV. CV risk factors were independently associated with AT at/prior to diagnosis in both cohorts; TET2 showed concordant associations with inferior OS, whereas associations of rare mutations with AML were exploratory. Leukocytosis, JAK2V617F VAF, and abnormal karyotype further defined outcome-specific risk. These parallel experiences provide a comprehensive reference for patient counseling and lifelong surveillance.

Giuseppe Gaetano Loscocco, MD, PhD: AOP Health - Honoraria; AOP, GSK, Novartis - Honoraria; Novartis - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony)